3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Endometrial Neoplasms
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Dexamethasone
338
Bortezomib
188
Lenalidomide
186
Cyclophosphamide
166
Melphalan
124
Calcium Dobesilate
108
daratumumab
95
fludarabine phosphate
69
carfilzomib
69
pomalidomide
68
Peripheral Blood Stem Cell Transplantation
64
Filgrastim
56
Thalidomide
55
Busulfan
53
Mycophenolic Acid
52
Tacrolimus
45
Granulocyte Colony-Stimulating Factor
45
ixazomib
43
fludarabine
42
Whole-Body Irradiation
40
Cyclosporine
35
Etoposide
33
dexamethasone acetate
31
Antilymphocyte Serum
31
isatuximab
29
dexamethasone 21-phosphate
26
Prednisone
26
elotuzumab
25
Biopsy
25
auricularum
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Multiple Myeloma
×
talazoparib
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled